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Background
Efficient triage in the Emergency Departments (ED) is
important to identify patients in need of urgent care.
Biomarker measurements may aid these clinical decisions.
suPAR, soluble urokinase-type plasminogen activator recep-
tor, is a non-specific biomarker reflecting inflammation and
is a strong prognostic marker for several diseases. This
study investigated suPAR’s predictive capacity to identify
high- and low-risk patients in the Emergency Department.
Method
This study was part of a prospective cohort study carried
out at Hillerød University Hospital (TRIAGE-study). The
prognostic value of suPAR was compared to the prognos-
tic value of triage category based on the information from
the systematic triage tool, Danish Emergency Process
Triage (DEPT) in prediction of 30-days mortality. Blood
samples were taken upon arrival to the ED. Patients
admitted to the ED from September 2013 to December
2013 were included in the study. suPAR levels were mea-
sured in EDTA-plasma using the CE/IVD approved
suPARnostic ELISA (ViroGates, Denmark).
Results
Serum was available for analysis of suPAR in 5,992
patients (94% of the admitted patients). Mean age was
59.8 years and 50.1% were female. The mean concentra-
tion of suPAR was 5.5 ng/ml (± 3.6) and there was a
significant correlation between suPAR level, CRP level
(R2 = 0.09), and leucocyte count (R2 = 0.02), p < 0.01
for both. Mortality at 30 days was 3.6%. ROC analyses
of the prognostic value of suPAR in relation to 30-day
mortality showed that the area under the curve (AUC)
was 0.85 (95% CI 0.82-0.87), similar analyses of the
triage category showed an AUC of 0.62 (95% c.i. 0.58-
0.66). Cox regression analysis of 30-day mortality in rela-
tion to suPAR quartiles showed that the hazard ratio for
the second quartile was 2.2, third quartile 6.5, and highest
quartile 38.4 (p < 0.001). In a multivariable analysis
including gender, age, CRP, leucocyte count, and triage
category, suPAR remained an independent predictor of
30-day mortality with a hazard ratio for second quartile
of 4.5, third quartile 8.3 and highest quartile 26.9.
Conclusion
In unselected patients admitted to an Emergency Depart-
ment, suPAR is an independent marker of short-term
mortality. suPAR could potentially help clinicians in the
initial risk assessment of acutely admitted patients.
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